Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats

G M Crews1, L Erickson, F Pan

  • 1Department of Basic Science, Astellas Research Institute of America, Evanston, Illinois 60201, USA.

Insights

Transforming growth factor-beta (TGF-beta) and vascular cell adhesion molecule (VCAM-1) levels correlate with chronic kidney rejection severity. Suppressing these molecules may ameliorate rejection, indicating their key role in transplant pathology.

Area of Science:

  • Transplantation immunology
  • Molecular biology
  • Renal pathology

Background:

  • Chronic rejection remains a significant challenge in organ transplantation.
  • Identifying molecular markers associated with chronic rejection is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the correlation between transforming growth factor-beta (TGF-beta) and vascular cell adhesion molecule (VCAM-1) expression levels and the severity of chronic kidney allograft rejection.
  • To assess the impact of different immunosuppressive regimens on these molecular markers and rejection severity.

Main Methods:

  • Rat kidney allograft and isograft models were established.
  • Grafts were treated with various regimens including tacrolimus (FK506), triptolide (PG490-88), and a leflunomide analogue (FK778).
  • Gene expression of TGF-beta and VCAM-1 was quantified using RT-PCR, and histological analysis was performed using the Modified Banff score.

Main Results:

  • Chronic rejection severity varied across treatment groups, being mild with FK778, moderate with PG490-88, and severe with FK506 and untreated allografts.
  • Expression levels of TGF-beta and VCAM-1 showed a strong positive correlation with the histological severity of chronic rejection.
  • Drug-induced suppression of TGF-beta and VCAM-1 expression was associated with reduced chronic rejection.

Conclusions:

  • TGF-beta and VCAM-1 are key molecular players in the pathogenesis of chronic kidney allograft rejection.
  • Monitoring and targeting TGF-beta and VCAM-1 expression may offer therapeutic strategies to mitigate chronic rejection.